Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | ADH4 | P08319 | 1/20 | 0.33 |
| ▸ | ADH7 | P40394 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6986477 | 1.00 | ADH1B (0.33) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL10768135 | 1.00 | ADH1B (0.33) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL10596506 | 1.00 | ADH1B (0.33) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL10596501 | 1.00 | ADH1B (0.33) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL10768126 | 1.00 | ADH1B (0.33) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL7400325 | 1.00 | ADH1B (0.33) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL10870592 | 0.97 | ADH1B (0.30) | ADH1BADH1CADH1AADH4ADH7 | |
| Acetic Acid SCHEMBL6988179 | 0.88 | LMNA (0.33) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL29860701 | 0.84 | ADH1B (0.36) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL4793553 | 0.77 | ADH1B (0.34) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859615-B2 | Compounds, compositions and methods for reducing toxicity and treating or preventing diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-14 | — | — | US | disclosed |
| US-8859615-B2 | Compounds, compositions and methods for reducing toxicity and treating or preventing diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-14 | — | — | US | disclosed |
| EP-2487149-A1 | METHOD FOR PRODUCING KETONE | JX Nippon Oil & Energy Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120197036-A1 | METHOD FOR MANUFACTURING KETONE | OSAKA UNIVERSITY (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2010025272-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-03-04 | — | — | WO | disclosed |
| EP-1089964-B1 | HYDRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2003-10-29 | — | — | EP | disclosed |
| US-6239151-B1 | TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES, OSTEOARTHRITIS, RESPIRATORY DISEASES, TUMORS, CACHEXIA, CARDIOVASCULAR DISEASES, FEVER, HAEMORRHAGE AND SEPSIS, HYDRAZINE DERIVATIVES, | HOFFMANN-LA ROCHE INC. | 2001-05-29 | — | — | US | disclosed |
| EP-1089964-A1 | HYDRAZINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000000465-A1 | HYDRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-01-06 | — | — | WO | disclosed |
| US-5502053-A | HIV protease inhibitor compounds | MERCK & CO., INC. (US) | 1996-03-26 | — | — | US | disclosed |
| US-4105697-A | Process for the preparation of α, β-ethylenic aldehydes | RHONE-POULENC INDUSTRIES (FR) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | TUBA1C, TUBB1, TOP1 | ADH1B 2564/4885ADH1C 3037/4885ADH1A 3516/4885 |
| US-20120197036-A1 | METHOD FOR MANUFACTURING KETONE | CBR1, CBR3, DUOX1 | ADH1B 148/4885ADH1C 6/4885ADH1A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.